Page 1

Exhibit 99.1 Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results ° ° First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed , Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep , rapid , selective lowering of disease - driving antibodies with BHV - 1300 in Graves ' disease and BHV - 1400 IgA Nephropathy , supporting advancement toward multiple registrational programs . Initiated pivotal Phase 3 study for BHV - 1300 in Graves ' disease with plans to initiate pivotal Phase 3 study for BHV - 1400 in IgAN in 2H 2026 . Ongoing clinical progress with opakalim across multiple epilepsy types ; pivotal readout on track for 2H 2026 Reported new clinical data for the selective Kv7.2 / 7.3 activator opakalim demonstrating durable seizure control across multiple epilepsy populations , including idiopathic generalized epilepsy , focal epilepsy , and KCNQ2 - developmental and epileptic encephalopathy , while reinforcing its differentiated tolerability profile . Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026 . ° New clinical data with BHV - 1530 , an FGFR3 - directed ADC using a novel Topolx payload , being presented at ESMO in October 2026 ; new Phase 1 data will provide clinically meaningful update to early Phase 1 data initially disclosed at R & D Day in May 2026 and will include signals of clinical activity demonstrated in ongoing Phase 1 , open - label , dose - escalation study in patients with advanced solid tumors . ° о Separately announced new clinical supply agreement with Regeneron to evaluate BHV - 1530 in combination with cemiplimab ( Libtayo® ) . Enrollment advances in advanced endometrial cancer expansion cohort with the next - generation TROP2- directed ADC BHV - 1510 in combination with Libtayo . Progress continues across broader pipeline : ° ° Patient enrollment is complete in the ongoing Phase 2 study of taldefgrobep alfa in obesity ; differentiated mechanism designed to promote high - quality weight loss while preserving lean muscle mass and improving overall metabolic health . Topline data expected during 2H 2026 . First - in - Human dosing commenced with orally administered , brain - penetrant PKM2 modulator , BHV - 8100 , a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders . Enrollment in Phase 2/3 early Parkinson's disease trial with brain - penetrant TYK2 / JAK1 inhibitor , BHV- 8000 , continues to advance . NEW HAVEN , Conn . , August 10 , 2026 / PRNewswire / - Biohaven Ltd. ( NYSE : BHVN ) ( Biohaven or the Company ) , a global clinical - stage biopharmaceutical company focused on the discovery , development and commercialization of life- changing therapies to treat a broad range of rare and common diseases , today reported financial results for the second quarter ended June 30 , 2026 , and provided a review of recent accomplishments and anticipated upcoming developments . Vlad Coric , M.D. , Chairman and Chief Executive Officer of Biohaven , commented , " What excites me most about Biohaven today is that we're no longer talking about scientific promise — we're watching new therapeutic approaches begin to work in patients . This year we've crossed important milestones across our portfolio , including advancing BHV - 1300 into pivotal development for Graves ' disease and generating compelling patient data from both our Graves ' disease and IgA nephropathy programs . We believe our MODE and TRAP platforms are doing something fundamentally different : selectively removing the proteins that drive disease while preserving normal immune function . If these data continue to translate into larger studies , extracellular protein degradation has the potential to reshape how autoimmune diseases are treated . " Dr. Coric continued , " Opakalim represents another example of our commitment to solving difficult biological problems with precision . For decades , patients with epilepsy have often had to choose between seizure control and living with burdensome central nervous system side effects like somnolence , dizziness , and cognitive impairment . Our goal is to change that equation . Across studies to date , opakalim has consistently demonstrated the potential to deliver meaningful seizure reduction with a differentiated tolerability profile from existing therapies . As we approach our